PL3830092T3 - Heteroaromatyczne modulatory receptorów nmda i ich zastosowania - Google Patents
Heteroaromatyczne modulatory receptorów nmda i ich zastosowaniaInfo
- Publication number
- PL3830092T3 PL3830092T3 PL19876025.8T PL19876025T PL3830092T3 PL 3830092 T3 PL3830092 T3 PL 3830092T3 PL 19876025 T PL19876025 T PL 19876025T PL 3830092 T3 PL3830092 T3 PL 3830092T3
- Authority
- PL
- Poland
- Prior art keywords
- heteroaromatic
- nmda receptor
- receptor modulators
- nmda
- modulators
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862714100P | 2018-08-03 | 2018-08-03 | |
PCT/US2019/044814 WO2020086136A2 (en) | 2018-08-03 | 2019-08-02 | Heteroaromatic nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3830092T3 true PL3830092T3 (pl) | 2023-11-13 |
Family
ID=69228330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19876025.8T PL3830092T3 (pl) | 2018-08-03 | 2019-08-02 | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
Country Status (36)
Country | Link |
---|---|
US (3) | US10584131B2 (pl) |
EP (2) | EP4223760A1 (pl) |
JP (1) | JP7319369B2 (pl) |
KR (1) | KR20210039432A (pl) |
CN (1) | CN112513047B (pl) |
AR (1) | AR115905A1 (pl) |
AU (1) | AU2019368147B2 (pl) |
BR (1) | BR112021001967A2 (pl) |
CA (1) | CA3108519A1 (pl) |
CL (1) | CL2021000294A1 (pl) |
CO (1) | CO2021002898A2 (pl) |
CR (1) | CR20210125A (pl) |
CU (1) | CU24647B1 (pl) |
CY (1) | CY1126144T1 (pl) |
DK (1) | DK3830092T3 (pl) |
DO (1) | DOP2021000025A (pl) |
EA (1) | EA202190431A1 (pl) |
EC (1) | ECSP21014902A (pl) |
ES (1) | ES2951872T3 (pl) |
FI (1) | FI3830092T3 (pl) |
HR (1) | HRP20230774T1 (pl) |
HU (1) | HUE062566T2 (pl) |
IL (1) | IL280474B2 (pl) |
JO (1) | JOP20210020A1 (pl) |
LT (1) | LT3830092T (pl) |
MA (1) | MA53351B1 (pl) |
MX (1) | MX2021001367A (pl) |
PE (1) | PE20210948A1 (pl) |
PH (1) | PH12021550242A1 (pl) |
PL (1) | PL3830092T3 (pl) |
PT (1) | PT3830092T (pl) |
RS (1) | RS64359B1 (pl) |
SG (1) | SG11202101125VA (pl) |
SI (1) | SI3830092T1 (pl) |
WO (1) | WO2020086136A2 (pl) |
ZA (1) | ZA202101273B (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3386591T (lt) * | 2015-12-09 | 2020-10-12 | Cadent Therapeutics, Inc. | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
LT3830092T (lt) | 2018-08-03 | 2023-09-11 | Novartis Ag | Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1067079A (en) | 1976-07-22 | 1979-11-27 | Yamanouchi Pharmaceutical Co. | Nitrogen-containing heterobicyclic compounds |
FR2549834B1 (fr) | 1983-07-25 | 1985-10-18 | Sanofi Sa | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques |
US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
AU6643694A (en) | 1993-05-21 | 1994-12-20 | Pentapharm Ag | 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones |
JP2000513375A (ja) | 1996-06-28 | 2000-10-10 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプター拮抗薬プロドラッグ |
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
KR100880972B1 (ko) | 2004-07-13 | 2009-02-03 | 에프. 호프만-라 로슈 아게 | 설폰아마이드 유도체 |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
CN101528703B (zh) | 2006-09-11 | 2011-09-07 | 欧加农股份有限公司 | 2-(1-氧代-1h-异喹啉-2-基)乙酰胺衍生物 |
CA2663161C (en) | 2006-09-11 | 2014-10-28 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
EP2425840B1 (en) | 2006-12-15 | 2015-04-08 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
EP1939187A1 (en) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
WO2008097538A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
EP2160389B1 (en) | 2007-04-18 | 2014-03-12 | Probiodrug AG | Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors |
WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
AU2008289573B2 (en) | 2007-08-21 | 2013-05-16 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
WO2009134973A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
US20110077248A1 (en) | 2008-05-29 | 2011-03-31 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine and related analogs as sirtuin modulators |
EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
JP5758292B2 (ja) | 2008-07-03 | 2015-08-05 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体 |
CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
CN102227417B (zh) | 2008-09-29 | 2015-09-16 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的色烯酮类似物 |
JP5053459B2 (ja) | 2009-01-12 | 2012-10-17 | アイカジェン, インコーポレイテッド | スルホンアミド誘導体 |
ES2540119T3 (es) | 2009-03-27 | 2015-07-08 | Abbvie Inc. | Compuestos como ligandos de receptores cannabinoides |
EP2264035A1 (en) | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
CA2776835A1 (en) | 2009-10-13 | 2011-04-21 | Msd Oss B.V. | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
EP2552907B1 (en) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
WO2012009688A1 (en) | 2010-07-16 | 2012-01-19 | Rockefeller University | Organic compounds |
EP2630136A1 (en) | 2010-10-21 | 2013-08-28 | Universität des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
NZ617987A (en) | 2011-05-10 | 2016-02-26 | Gilead Sciences Inc | Fused heterocyclic compounds as sodium channel modulators |
EP2760830B1 (en) | 2011-09-27 | 2016-08-03 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
EP2760840B1 (en) | 2011-09-30 | 2015-08-12 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
EP2760839B1 (en) | 2011-09-30 | 2015-11-25 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
PL3628320T3 (pl) | 2011-11-11 | 2022-07-25 | Gilead Apollo, Llc | Inhibitory acc i ich zastosowania |
KR102137087B1 (ko) | 2012-02-10 | 2020-07-24 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
WO2014066743A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
WO2015007453A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
TW201609656A (zh) | 2013-09-26 | 2016-03-16 | 美涅莫辛製藥公司 | Nr2a之n-芳基甲基磺醯胺負向調節劑 |
SI3055315T1 (sl) | 2013-10-11 | 2018-11-30 | F. Hoffmann-La Roche Ag | Tiazolopirimidinoni kot modulatorji aktivnosti receptorjev NMDA |
WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体 |
CN103664877A (zh) | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
US9617226B2 (en) | 2014-09-05 | 2017-04-11 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
JP6847851B2 (ja) | 2015-04-15 | 2021-03-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Nmda受容体のモジュレーターとしてのピリドピリミジノン及びその使用 |
CA3002070A1 (en) | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
LT3386591T (lt) | 2015-12-09 | 2020-10-12 | Cadent Therapeutics, Inc. | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
US20170305861A1 (en) | 2016-04-25 | 2017-10-26 | Immunomet Therapeutics, Inc | Heteroaryl compounds comprising nitrogen and use thereof |
WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
RS62872B1 (sr) | 2017-09-27 | 2022-02-28 | Incyte Corp | Soli derivata pirrolotriazina korisne kao tam inhibitori |
LT3830092T (lt) | 2018-08-03 | 2023-09-11 | Novartis Ag | Heteroaromatiniai nmda receptorių moduliatoriai ir jų panaudojimai |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
-
2019
- 2019-08-02 LT LTEPPCT/US2019/044814T patent/LT3830092T/lt unknown
- 2019-08-02 SI SI201930580T patent/SI3830092T1/sl unknown
- 2019-08-02 CA CA3108519A patent/CA3108519A1/en active Pending
- 2019-08-02 ES ES19876025T patent/ES2951872T3/es active Active
- 2019-08-02 JO JOP/2021/0020A patent/JOP20210020A1/ar unknown
- 2019-08-02 BR BR112021001967-7A patent/BR112021001967A2/pt unknown
- 2019-08-02 EP EP23165151.4A patent/EP4223760A1/en active Pending
- 2019-08-02 AR ARP190102209A patent/AR115905A1/es unknown
- 2019-08-02 PE PE2021000151A patent/PE20210948A1/es unknown
- 2019-08-02 JP JP2021529249A patent/JP7319369B2/ja active Active
- 2019-08-02 SG SG11202101125VA patent/SG11202101125VA/en unknown
- 2019-08-02 FI FIEP19876025.8T patent/FI3830092T3/fi active
- 2019-08-02 HU HUE19876025A patent/HUE062566T2/hu unknown
- 2019-08-02 CR CR20210125A patent/CR20210125A/es unknown
- 2019-08-02 CU CU2021000013A patent/CU24647B1/es unknown
- 2019-08-02 WO PCT/US2019/044814 patent/WO2020086136A2/en active Application Filing
- 2019-08-02 PT PT198760258T patent/PT3830092T/pt unknown
- 2019-08-02 US US16/530,274 patent/US10584131B2/en active Active
- 2019-08-02 CN CN201980051645.9A patent/CN112513047B/zh active Active
- 2019-08-02 PL PL19876025.8T patent/PL3830092T3/pl unknown
- 2019-08-02 KR KR1020217006300A patent/KR20210039432A/ko active Search and Examination
- 2019-08-02 EP EP19876025.8A patent/EP3830092B1/en active Active
- 2019-08-02 MA MA53351A patent/MA53351B1/fr unknown
- 2019-08-02 AU AU2019368147A patent/AU2019368147B2/en active Active
- 2019-08-02 HR HRP20230774TT patent/HRP20230774T1/hr unknown
- 2019-08-02 EA EA202190431A patent/EA202190431A1/ru unknown
- 2019-08-02 MX MX2021001367A patent/MX2021001367A/es unknown
- 2019-08-02 RS RS20230563A patent/RS64359B1/sr unknown
- 2019-08-02 IL IL280474A patent/IL280474B2/en unknown
- 2019-08-02 DK DK19876025.8T patent/DK3830092T3/da active
- 2019-11-08 US US16/678,806 patent/US10752633B2/en active Active
-
2021
- 2021-02-01 PH PH12021550242A patent/PH12021550242A1/en unknown
- 2021-02-02 DO DO2021000025A patent/DOP2021000025A/es unknown
- 2021-02-03 CL CL2021000294A patent/CL2021000294A1/es unknown
- 2021-02-12 US US17/174,826 patent/US11542264B2/en active Active
- 2021-02-25 ZA ZA2021/01273A patent/ZA202101273B/en unknown
- 2021-03-03 CO CONC2021/0002898A patent/CO2021002898A2/es unknown
- 2021-03-03 EC ECSENADI202114902A patent/ECSP21014902A/es unknown
-
2023
- 2023-08-02 CY CY20231100387T patent/CY1126144T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL276332A (en) | Spiro-lactam NMDA receptor modulators and their use | |
IL276330A (en) | Spiro-lactam NMDA receptor modulators and their use | |
IL264514B (en) | Spiro-lactam nmda receptor modulators and their uses | |
IL286107A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EP3490994B8 (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
EP3490565A4 (en) | CHEMOKIN RECEPTOR MODULATORS AND USES THEREOF | |
DK3830092T3 (en) | Heteroaromatic nmda receptor modulators and uses thereof | |
IL288858A (en) | Transmuted heteroaromatic pyrazolopyridines and their use as glun2b receptor modulators | |
IL276295A (en) | Modulators of chemokine receptors and their uses | |
EP3558318A4 (en) | NMDA RECEPTOR MODULATORS AND USES THEREOF | |
SI3386591T1 (sl) | Heteroaromatski NMDA receptorski modulatorji in njihove uporabe | |
HK1245259A1 (zh) | 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途 | |
ZA201905511B (en) | Rorgamma modulators and uses thereof | |
ZA201905513B (en) | Rorgamma modulators and uses thereof | |
IL289575A (en) | nmda receptor modulators |